ROCKVILLE, Md., Feb. 25, 2025 /PRNewswire/ -- REGENXBIO Inc. (Nasdaq: RGNX) today announced it will participate in the following investor conferences:
TD Cowen's 45th Annual Health Care Conference
Fireside Chat: Wednesday, March 5 at 1:10pm ET
Location: Boston, MA
Leerink Partners Global Healthcare Conference
Fireside Chat: Tuesday, March 11 at 9:20am ET
Location: Miami, FL
Barclays 27th Annual Global Healthcare Conference
Fireside Chat: Wednesday, March 12 at 3:30pm ET
Location: Miami, FL
UBS Virtual CNS Day
Fireside Chat: Monday, March 17 at 10:00am ET
Location: Virtual
RBC Inaugural Virtual Ophthalmology Conference
Fireside Chat: April 3 at 8:15am ET
Location: Virtual
Live webcasts of select fireside chats can be accessed in the Investors section of REGENXBIO's website at www.regenxbio.com. An archived replay of the webcast will be available for approximately 30 days following the presentation.
ABOUT REGENXBIO Inc.
REGENXBIO is a leading clinical-stage biotechnology company seeking to improve lives through the curative potential of gene therapy. Since its founding in 2009, REGENXBIO has pioneered the development of AAV Therapeutics, an innovative class of gene therapy medicines. REGENXBIO is advancing a pipeline of AAV Therapeutics for rare and retinal diseases, including RGX-202 for the treatment of Duchenne, ABBV-RGX-314 for the treatment of wet AMD and diabetic retinopathy, being developed in collaboration with AbbVie, and RGX-121 for the treatment of MPS II. Thousands of patients have been treated with REGENXBIO's AAV Therapeutic platform, including Novartis' Zolgensma® for children with spinal muscular atrophy. Designed to be one-time treatments, AAV Therapeutics have the potential to change the way healthcare is delivered for millions of people. For more information, please visit WWW.REGENXBIO.COM.
Contacts:
Dana Cormack
Corporate Communications
This email address is being protected from spambots. You need JavaScript enabled to view it.
Investors:
George E. MacDougall
Investor Relations
This email address is being protected from spambots. You need JavaScript enabled to view it.
| Last Trade: | US$10.92 |
| Daily Change: | -1.25 -10.27 |
| Daily Volume: | 966,573 |
| Market Cap: | US$551.570M |
October 09, 2025 October 06, 2025 September 29, 2025 September 05, 2025 August 18, 2025 | |
Chimerix is on a mission to develop medicines that meaningfully improve and extend the lives of patients facing deadly diseases. The company is devoted to filling gaps in the treatment paradigm. Chimerix’s most advanced clinical-stage program is in development for H3 K27M-mutant glioma....
CLICK TO LEARN MORE
Terns Pharmaceuticals is a clinical-stage biopharmaceutical company developing a portfolio of small-molecule product candidates to address serious diseases, including oncology and obesity. Terns’ pipeline contains three clinical stage development programs including GLP-1 receptor...
CLICK TO LEARN MORE
